Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology
November 22, 2021 07:00 ET
|
Laboratoris Sanifit S.L.
Press Release Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology Vifor Pharma to acquire Sanifit, a clinical-stage cardio-renal biopharmaceutical company focused...
Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology
November 22, 2021 01:05 ET
|
Laboratoris Sanifit S.L.
Press Release Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology Vifor Pharma to acquire Sanifit, a clinical-stage cardio-renal biopharmaceutical company...
Sanifit Granted Orphan Drug Designation by the FDA for SNF472 for the Treatment of Peripheral Arterial Disease in Patients with End-stage Kidney Disease
February 10, 2021 07:00 ET
|
Laboratoris Sanifit S.L.
Sanifit Granted Orphan Drug Designation by the FDA for SNF472 for the Treatment of Peripheral Arterial Disease in Patients with End-stage Kidney Disease Palma, Spain and San Diego, USA, February 10,...
Sanifit Appoints Adam Levy as Chief Financial Officer
August 20, 2020 07:00 ET
|
Laboratoris Sanifit S.L.
Sanifit Appoints Adam Levy as Chief Financial Officer Palma, Spain and San Diego, USA, 20 August 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for...
Sanifit to start new clinical development program of SNF472 in End Stage Kidney Disease patients with Peripheral Artery Disease
July 20, 2020 07:00 ET
|
Laboratoris Sanifit S.L.
Sanifit to start new clinical development program of SNF472 in End Stage Kidney Disease patients with Peripheral Artery Disease FDA has agreed to key aspects of the clinical program, including...
First patient dosed in pivotal phase 3 trial of SNF472 in calciphylaxis
February 13, 2020 07:00 ET
|
Laboratoris Sanifit S.L.
First patient dosed in pivotal phase 3 trial of SNF472 in calciphylaxis First patient dosed in phase 3 trial of SNF472 for the treatment of calcific uremic arteriolopathy (CUA) or calciphylaxis ...
Positive data from Sanifit’s Phase 2b CaLIPSO trial of SNF472 published in Circulation
November 12, 2019 07:00 ET
|
Laboratoris Sanifit S.L.
Positive data from Sanifit’s Phase 2b CaLIPSO trial of SNF472 published in Circulation SNF472 significantly reduced progression of cardiovascular calcification in patients with end stage kidney...
Positive data from Sanifit’s Phase 2b CaLIPSO trial of SNF472 published in Circulation
November 12, 2019 02:00 ET
|
Laboratoris Sanifit S.L.
Positive data from Sanifit’s Phase 2b CaLIPSO trial of SNF472 published in Circulation SNF472 significantly reduced progression of cardiovascular calcification in patients with end stage kidney...
Sanifit announces that Phase 2b CaLIPSO trial of SNF472 met its primary endpoint
October 30, 2019 07:00 ET
|
Laboratoris Sanifit S.L.
Sanifit announces that the Phase 2b CaLIPSO trial of SNF472 met its primary endpoint in slowing the progression of cardiovascular calcification in patients on hemodialysis Top line data to be...
Sanifit named as one of 2019’s “Fierce 15” biotechnology companies by FierceBiotech
September 23, 2019 09:00 ET
|
Laboratoris Sanifit S.L.
Sanifit named as one of 2019’s “Fierce 15” biotechnology companies by FierceBiotech Palma, Spain and San Diego, USA, 23 September 2019 – Sanifit, a clinical-stage biopharmaceutical company focused on...